These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31835137)

  • 1. HPV33+ HNSCC is associated with poor prognosis and has unique genomic and immunologic landscapes.
    Chatfield-Reed K; Gui S; O'Neill WQ; Teknos TN; Pan Q
    Oral Oncol; 2020 Jan; 100():104488. PubMed ID: 31835137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models.
    Facompre ND; Rajagopalan P; Sahu V; Pearson AT; Montone KT; James CD; Gleber-Netto FO; Weinstein GS; Jalaly J; Lin A; Rustgi AK; Nakagawa H; Califano JA; Pickering CR; White EA; Windle BE; Morgan IM; Cohen RB; Gimotty PA; Basu D
    Int J Cancer; 2020 Dec; 147(11):3236-3249. PubMed ID: 32478869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
    Messerschmidt C; Obermayer B; Klinghammer K; Ochsenreither S; Treue D; Stenzinger A; Glimm H; Fröhling S; Kindler T; Brandts CH; Schulze-Osthoff K; Weichert W; Tinhofer I; Klauschen F; Keilholz U; Beule D; Rieke DT
    Int J Cancer; 2020 Oct; 147(8):2293-2302. PubMed ID: 32468570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Immune-Related Prognostic Biomarkers Associated with HPV-Positive Head and Neck Squamous Cell Carcinoma.
    Chen Y; Nie J; Li X; Fan T; Deng X; Liang D; Song G
    J Immunol Res; 2021; 2021():6661625. PubMed ID: 33506058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV Meets APOBEC: New Players in Head and Neck Cancer.
    Riva G; Albano C; Gugliesi F; Pasquero S; Pacheco SFC; Pecorari G; Landolfo S; Biolatti M; Dell'Oste V
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival-related indicators ALOX12B and SPRR1A are associated with DNA damage repair and tumor microenvironment status in HPV 16-negative head and neck squamous cell carcinoma patients.
    Li J; Tang LL; Ma J
    BMC Cancer; 2022 Jun; 22(1):714. PubMed ID: 35768785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of the tumor microbiome, molecular profiles, and immune cell abundances by HPV status in mucosal head and neck cancers and their impact on survival.
    Upadhyay R; Dhakal A; Wheeler C; Hoyd R; Jagjit Singh M; Karivedu V; Bhateja P; Bonomi M; Valentin S; Gamez ME; Konieczkowski DJ; Baliga S; Grecula JC; Blakaj DM; Gogineni E; Mitchell DL; Denko NC; Spakowicz D; Jhawar SR
    Cancer Biol Ther; 2024 Dec; 25(1):2350249. PubMed ID: 38722731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC.
    Gui S; O'Neill WQ; Teknos TN; Pan Q
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC).
    Saba NF; Dinasarapu AR; Magliocca KR; Dwivedi B; Seby S; Qin ZS; Patel M; Griffith CC; Wang X; El-Deiry M; Steuer CE; Kowalski J; Shin DM; Zwick ME; Chen ZG
    PLoS One; 2020; 15(9):e0238497. PubMed ID: 32986729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Tumor Site With the Prognosis and Immunogenomic Landscape of Human Papillomavirus-Related Head and Neck and Cervical Cancers.
    Zhu G; Amin N; Herberg ME; Maroun CA; Wang H; Guller M; Gourin CG; Rooper LM; Vosler PS; Tan M; D'Souza G; Koch WM; Eisele DW; Seiwert TY; Fakhry C; Pardoll DM; Mandal R
    JAMA Otolaryngol Head Neck Surg; 2022 Jan; 148(1):70-79. PubMed ID: 34792560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The frequency of high-risk human papillomavirus types, HPV16 lineages, and their relationship with p16
    Pakdel F; Farhadi A; Pakdel T; Andishe-Tadbir A; Alavi P; Behzad-Behbahani A; Ashraf MJ
    Braz J Microbiol; 2021 Mar; 52(1):195-206. PubMed ID: 33169334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers.
    Koneva LA; Zhang Y; Virani S; Hall PB; McHugh JB; Chepeha DB; Wolf GT; Carey TE; Rozek LS; Sartor MA
    Mol Cancer Res; 2018 Jan; 16(1):90-102. PubMed ID: 28928286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?
    Yoo SH; Ock CY; Keam B; Park SJ; Kim TM; Kim JH; Jeon YK; Chung EJ; Kwon SK; Hah JH; Kwon TK; Jung KC; Kim DW; Wu HG; Sung MW; Heo DS
    Korean J Intern Med; 2019 Nov; 34(6):1313-1323. PubMed ID: 30428646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined P16 and human papillomavirus testing predicts head and neck cancer survival.
    Salazar CR; Anayannis N; Smith RV; Wang Y; Haigentz M; Garg M; Schiff BA; Kawachi N; Elman J; Belbin TJ; Prystowsky MB; Burk RD; Schlecht NF
    Int J Cancer; 2014 Nov; 135(10):2404-12. PubMed ID: 24706381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.
    Riva G; Pecorari G; Biolatti M; Pautasso S; Lo Cigno I; Garzaro M; Dell'Oste V; Landolfo S
    Mol Biol Rep; 2019 Jun; 46(3):3333-3347. PubMed ID: 30980272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection.
    López RV; Levi JE; Eluf-Neto J; Koifman RJ; Koifman S; Curado MP; Michaluart-Junior P; Figueiredo DL; Saggioro FP; de Carvalho MB; Kowalski LP; Abrahão M; de Góis-Filho F; Tajara EH; Waterboer T; Boffetta P; Brennan P; Wünsch-Filho V
    Cancer Causes Control; 2014 Apr; 25(4):461-71. PubMed ID: 24474236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Epigenomic Alterations in HPV16+ Head and Neck Squamous Cell Carcinomas.
    Berglund A; Muenyi C; Siegel EM; Ajidahun A; Eschrich SA; Wong D; Hendrick LE; Putney RM; Kim S; Hayes DN; Shibata D
    Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):858-869. PubMed ID: 35064062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type I conventional dendritic cells and CD8
    Kirchner J; Plesca I; Rothe R; Resag A; Löck S; Benešová I; Rupp L; Linge A; Wehner R; Krause M; Schmitz M
    Front Immunol; 2024; 15():1414298. PubMed ID: 38938577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer.
    Wichmann G; Rosolowski M; Krohn K; Kreuz M; Boehm A; Reiche A; Scharrer U; Halama D; Bertolini J; Bauer U; Holzinger D; Pawlita M; Hess J; Engel C; Hasenclever D; Scholz M; Ahnert P; Kirsten H; Hemprich A; Wittekind C; Herbarth O; Horn F; Dietz A; Loeffler M;
    Int J Cancer; 2015 Dec; 137(12):2846-57. PubMed ID: 26095926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.